Six-year findings from laser in glaucoma and ocular hypertension (LiGHT)
In visual field progression results, SLT was superior to ocular drops as first-line treatment for patients with glaucoma
A recent retrospective analysis of data from the Laser in Glaucoma and Ocular Hypertension (LiGHT)1 Trial found that selective laser trabeculoplasty (SLT) as a first-line treatment was superior to glaucoma medication for reducing the rate of visual field (VF) loss in patients with ocular hypertension and glaucoma. This conclusion was presented by investigators including first author Giovanni Montesano, MD from the NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, and City, University of London, Optometry and Visual Sciences, London. He reported the results at the 2024 American Academy of Ophthalmology annual meeting in Chicago.
Giovanni Montesano, MD, Moorfields Eye Hospital and City, University of London
Both the LiGHT trial and the HORIZON trial2 have reported that VF progression can occur at different rates even when treated to the same target intraocular pressure (IOP). Dr Montesano and colleagues from the LiGHT Trial Study Group took their research a step forward in the study under discussion.
They published a method to better characterise the distribution of rates of VF progression3 and applied the methodology to analyse the 6-year rate of true VF progression in the LiGHT trial in patients with open-angle glaucoma or ocular hypertension who underwent SLT or received topical medication as first treatment. Eyes were included with the more positive mean deviation of each patient with at least three reliable VFs. The patients were followed for up to 6 years with VF tests and IOP measurements.
The mean rate of MD loss was compared between the two treatments using a Bayesian hierarchical model3 that separates the underlying distribution of “true” progression rates from perimetric noise and learning, the investigators explained.
Analysis results
A total of 710 eyes were included and randomised; 354 eyes underwent SLT as the first-line treatment and the remainder were treated with topical medications. The eyes underwent a mean of 12 ± 4 VF tests per eye.
The baseline MDs in the SLT group and the medication group, respectively, were −2.15 ± 2.69 decibels (dB) and −2.13 ± 2.84 (P = 0.72).
“The ‘true’ MD rate of VF progression was 29% slower in the SLT-1st arm, −0.26 (−0.31, −0.21) dB/year (mean [95%-credible intervals]) compared to −0.37 (−0.43, −0.31) for the drops-first arm (P = 0.006),” Dr Montesano reported.
The study showed that the estimated proportion of very fast progressors (true rate < -1 dB/year) was 2.1 [0.8, 4.1]% in the SLT-first arm and 6.5 [4.0, 9.7)% in the drops-first arm (odds ratio [OR] = 3.80 [1.39, 9.06]). The estimated proportion of fast progressors (true rate < -0.5 dB/year) was 14.4 [9.1, 20.2]% in the SLT-first arm and 25.4 [20.0, 31.1]% in the drops-first arm (OR = 2.15 [1.22, 3.65]), the investigators reported.
In commenting on the results, Dr Montesano and colleagues stated, “These results show evidence of a significantly slower rate of progression in eyes receiving SLT as initial treatment compared to medications. These results confirm previous evidence from the LiGHT trial with a more robust statistical methodology and a longer follow-up. The specific choice of modelling allows an estimation of the proportional effect on the true rates of progression, reducing the bias introduced by learning.3 This is particularly important to improve generalizability of the results when analysing data from newly diagnosed patients, who are likely naïve to VF testing.”
